Candel Therapeutics, Inc.

NasdaqGM:CADL Stock Report

Market Cap: US$341.3m

Candel Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:CADL Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
15 Jan 25SellUS$75,342William NicholsIndividual10,428US$7.23
15 Jan 25SellUS$156,811Paul-Peter TakIndividual21,704US$7.23
15 Jan 25SellUS$97,783Francesca BaroneIndividual13,534US$7.23
15 Jan 25SellUS$103,476Seshu TyagarajanIndividual14,322US$7.23
15 Jan 25SellUS$68,717Charles SchochIndividual9,511US$7.23
08 Jan 25SellUS$119,534Seshu TyagarajanIndividual14,545US$8.22
08 Jan 25SellUS$112,367Francesca BaroneIndividual13,673US$8.22
08 Jan 25SellUS$88,749William NicholsIndividual10,799US$8.22
08 Jan 25SellUS$81,944Charles SchochIndividual9,971US$8.22
08 Jan 25SellUS$173,996Paul-Peter TakIndividual21,172US$8.22
16 Dec 24BuyUS$3,000,000Paul ManningIndividual500,000US$6.00
16 Dec 24BuyUS$4,500,000Tiger Lily CapitalCompany750,000US$6.00
29 Nov 24SellUS$63,482William NicholsIndividual13,935US$4.56
29 Nov 24SellUS$100,592Francesca BaroneIndividual22,081US$4.56
29 Nov 24SellUS$222,527Paul-Peter TakIndividual48,847US$4.56
29 Nov 24SellUS$92,898Seshu TyagarajanIndividual20,392US$4.56
15 Oct 24SellUS$243,834Laura AguilarIndividual40,412US$6.05
03 Oct 24SellUS$199,087Laura AguilarIndividual28,788US$6.92

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of CADL?
Owner TypeNumber of SharesOwnership Percentage
Private Companies4,088,0427.67%
Individual Insiders5,328,5369.99%
General Public20,003,20637.5%
Institutions23,904,29044.8%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 66.2%.

Top Shareholders

Top 25 shareholders own 58.72% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
13.3%
FMR LLC
7,085,216US$45.3m80.6%no data
7.3%
Paul Manning
3,894,069US$24.9m37.9%no data
4.84%
Acorn Bioventures
2,580,517US$16.5m19.9%8.49%
4.57%
Baker Bros. Advisors LP
2,437,189US$15.6m-18.3%0.1%
3.89%
Estuardo Aguilar-Cordova 2020 Irrevocable Trust
2,074,942US$13.3m0%no data
3.78%
Laura K. Aguilar 2020 Irrevocable Trust
2,013,100US$12.9m0%no data
3.35%
The Vanguard Group, Inc.
1,787,549US$11.4m2.96%no data
3.31%
BlackRock, Inc.
1,763,770US$11.3m49%no data
2.44%
Tiger Lily Capital
1,303,752US$8.3m0%89.05%
1.7%
Geode Capital Management, LLC
903,970US$5.8m31.5%no data
1.65%
Portolan Capital Management, LLC
881,184US$5.6m16.9%0.33%
1.46%
Halter Ferguson Financial, Inc.
776,516US$5.0m12%1.63%
1.06%
State Street Global Advisors, Inc.
563,404US$3.6m0.43%no data
1.03%
Christopher Martell
546,863US$3.5m-16.9%no data
0.76%
Sands Capital Ventures, LLC
405,837US$2.6m0%0.54%
0.75%
Banor Capital Ltd.
398,826US$2.6m0%0.75%
0.5%
Paul-Peter Tak
268,566US$1.7m19%no data
0.45%
Susquehanna International Group, LLP, Asset Management Arm
241,175US$1.5m-18.1%no data
0.44%
Northern Trust Global Investments
235,536US$1.5m42.7%no data
0.44%
Marshall Wace LLP
234,597US$1.5m0%no data
0.39%
Millennium Management LLC
208,609US$1.3m560%no data
0.37%
Franklin Resources, Inc.
197,388US$1.3m0%no data
0.37%
Tanager Wealth Management LLP
196,631US$1.3m0%0.14%
0.35%
UBS Asset Management AG
187,094US$1.2m19.3%no data
0.24%
Bank of America Corporation, Asset Management Arm
127,149US$813.8k91.5%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/08/14 23:34
End of Day Share Price 2025/08/14 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Candel Therapeutics, Inc. is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Evan SeigermanBMO Capital Markets Equity Research
Alec StranahanBofA Global Research
Brian Kemp DolliverBrookline Capital Markets